Teruya, Shuzo
Okamura, Tomohisa
Komai, Toshihiko
Inoue, Mariko
Iwasaki, Yukiko
Sumitomo, Shuji http://orcid.org/0000-0003-4980-2664
Shoda, Hirofumi
Yamamoto, Kazuhiko
Fujio, Keishi
Article History
Received: 2 March 2018
Accepted: 19 April 2018
First Online: 4 May 2018
Competing Interests
: T.O. received financial support or fees from Chugai and Bristol-Myers Squibb (BMS). K.Y. received financial support or fees from AbbVie, Astellas, BMS, Daiichi-Sankyo, Mitsubishi Tanabe, Pfizer, Sanofi, Santen, Takeda, Teijin, Boehringer Ingelheim, Chugai, Eisai, Ono, Taisho Toyama, UCB, ImmunoFuture, Asahi Kasei, Janssen, and NIPPON KAYAKU. K.F. received financial support or fees from Astellas, BMS, Daiichi-Sankyo, Mitsubishi Tanabe, Pfizer, Santen, Takeda, Chugai, Eisai, Taisho Toyama, UCB, Janssen, and NIPPON KAYAKU. The remaining authors declare no competing financial interests. T.K., T.O., K.Y., and K.F. received patent-licensing arrangements with Chugai.